A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy

Tumor mutational burden (TMB), a surrogate for tumor neoepitope burden, is used as a pan-tumor biomarker to identify patients who may benefit from anti-program cell death 1 (PD1) immunotherapy, but it is an imperfect biomarker. Multiple additional genomic characteristics are associated with anti-PD1...

Descripción completa

Detalles Bibliográficos
Autores principales: Bigelow, Emma, Saria, Suchi, Piening, Brian, Curti, Brendan, Dowdell, Alexa, Weerasinghe, Roshanthi, Bifulco, Carlo, Urba, Walter, Finkelstein, Noam, Fertig, Elana J, Baras, Alex, Zaidi, Neeha, Jaffee, Elizabeth, Yarchoan, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685115/
https://www.ncbi.nlm.nih.gov/pubmed/36439024
http://dx.doi.org/10.1177/11769351221136081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685115/
https://www.ncbi.nlm.nih.gov/pubmed/36439024
http://dx.doi.org/10.1177/11769351221136081

Ejemplares similares